Ocular Changes Associated with Topiramate

Basit Öğe Kaydı
dc.contributor.authorOzturk, Banu Turgut
dc.contributor.authorGenc, Emine
dc.contributor.authorTokgoz, Mine
dc.contributor.authorKerimoglu, Hurkan
dc.contributor.authorGenc, Bulent Oguz
dc.date.accessioned2020-03-26T18:15:28Z
dc.date.available2020-03-26T18:15:28Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: To determine the changes in refractive error, and the cornea, anterior chamber, and retina induced by topiramate. Methods: The study included 76 eyes of 38 patients that began to use topiramate due to migraine. Following ophthalmological examination, all of the patients underwent central corneal thickness (CCT), anterior chamber volume (ACV), anterior chamber depth (ACD), and anterior chamber angle (ACA) measurement using a Scheimpflug camera, as well as macular thickness, retinal and retinal nerve fiber layer thickness (RNFLT) measurements using optical coherence tomography (OCT). These procedures were repeated 15, 30, and 90 days after the initiation of topiramate therapy. Results: The median refractive error value showed a statistically significant increase from -0.25 diopters (D) to -0.62 D at the 90th day follow-up (P < 0.001). Mean CCT was 570.56 mu m before treatment and increased to 573.69 mu m at the 15th day follow-up, 575.31 mu m at the 30th day follow-up, and 574.56 mu m at the 90th day follow-up; however, these changes were not statistically significant. Mean ACV, ACD, and ACA did not exhibit statistically significant changes. Mean retinal thickness (RT) increased during the treatment from 263.46 mu m to 271.60 mu m, which was not statistically significant. The initial mean RNFLT was 100.56 +/- 15.36 mu m and significantly increased to 110.2 +/- 8.41 mu m and 111.03 +/- 14.59 mu m at the 30th and 90th day follow-ups, respectively (P = 0.01 and P = 0.004, respectively). Conclusions: During the 3-month follow-up of patients using topiramate 50 mg d(-1) significant myopic shift and an increase in RNFLT were observed. Further studies are warranted in order to assess the effects of topiramate when used long term and at higher doses.en_US
dc.identifier.doi10.3109/02713683.2010.529540en_US
dc.identifier.endpage52en_US
dc.identifier.issn0271-3683en_US
dc.identifier.issn1460-2202en_US
dc.identifier.issue1en_US
dc.identifier.pmid21174597en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage47en_US
dc.identifier.urihttps://dx.doi.org/10.3109/02713683.2010.529540
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26685
dc.identifier.volume36en_US
dc.identifier.wosWOS:000285513500008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS INCen_US
dc.relation.ispartofCURRENT EYE RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAnterior chamberen_US
dc.subjectCorneal thicknessen_US
dc.subjectRetinal nerve fiber layer thicknessen_US
dc.subjectRetinal thicknessen_US
dc.subjectTopiramateen_US
dc.titleOcular Changes Associated with Topiramateen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu